ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
A Nanobody-LNP Platform for Targeting and Relicensing Dendritic Cells for Potent Cancer Immunotherapy.
Shugang Qin et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.